SCHEDULE: Trill AB & Jan Stahlberg Boost DiaMedica Stake to 15.02%

Trill AB and Jan Stahlberg have reported a combined beneficial ownership of 15.02% of DiaMedica Therapeutics Inc. common shares.

Summary

• Trill AB and Jan Stahlberg collectively beneficially own 7,764,465 common shares of DiaMedica Therapeutics Inc.
• This represents 15.02% of the company's outstanding common shares.
• The percentage is based on 51,688,913 shares outstanding as of August 8, 2025.
• Jan Stahlberg is a Board Member and beneficial owner of Trill AB, which is the record holder of the shares.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating a change in previously reported ownership.

Sentiment

Score: 7

Explanation: The filing indicates a significant and stable beneficial ownership stake by an institutional investor and a board member, suggesting strong confidence in the company. While it's a routine disclosure, the size of the stake and insider involvement are positive signals.

Positives

• A significant ownership stake by Trill AB and Jan Stahlberg, totaling 15.02%, indicates strong conviction in DiaMedica Therapeutics Inc.
• Jan Stahlberg's dual role as a Board Member and beneficial owner of Trill AB suggests alignment between a key insider and a major institutional investor.

Negatives

• No specific negative information is disclosed in this beneficial ownership report.

Risks

• No specific risks are mentioned in this Schedule 13G filing beyond the general market risks associated with holding common shares.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing indicates a significant, stable ownership stake by a Swedish investment entity and a key insider in DiaMedica Therapeutics Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. Such substantial institutional and insider ownership can be viewed positively, suggesting confidence in the company's long-term prospects within its competitive industry.

Comparison to Industry Standards

• A 15.02% beneficial ownership stake by an institutional investor and an insider is a substantial position, often exceeding typical passive investment thresholds seen in many biotech or pharmaceutical companies where institutional ownership might be more fragmented.
• Compared to other small-to-mid cap biotechnology firms, a single entity holding over 15% can provide a degree of stability and potentially influence strategic decisions, which is not uncommon for early-stage or specialized companies.

Management Changes

Corporate Governance

Legal Proceedings

• No legal or regulatory matters are mentioned in this filing.

Related Party Transactions

• The filing indicates Jan Stahlberg is a Board Member and beneficial owner of Trill AB, which is the record holder of the shares. This relationship is disclosed as part of the beneficial ownership structure.

Stakeholder Impact

• Shareholders: The significant stake held by Trill AB and Jan Stahlberg may provide a sense of stability and confidence, potentially influencing investor sentiment positively due to strong insider and institutional alignment.
• Management: The substantial ownership by a board member and associated entity could imply a more engaged and potentially influential shareholder, aligning interests with long-term strategic goals.

Next Steps

• The filing does not explicitly mention any future actions, events, or milestones for the company or the reporting persons beyond the regulatory requirement to update beneficial ownership.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant beneficial ownership stake by Trill AB and Jan Stahlberg, a board member. While the 15.02% stake indicates strong conviction and alignment, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' position for existing investors who might view this as a positive signal of long-term commitment, but it lacks the fundamental catalysts for a stronger recommendation.

Keywords

DiaMedica Therapeutics, Trill AB, Jan Stahlberg, Beneficial Ownership, SEC Filing, Schedule 13G, Common Shares, Institutional Investor, Biotechnology, Pharmaceuticals